Is SRTA diluting shareholders?

Read three numbers together: shares outstanding over time (89.3M as of 2026-10-26), warrants that can convert into new shares, and how much cash runway remains (~8.61986343378174 months). A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

Strata Critical Medical, Inc. (SRTA)

CIK 1779128 · all EDGAR filings →

Overall dilution risk

HIGHworst of 3 computed sub-ratings (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

not every sub-rating was computable; treat as a floor

Offering ability

HIGHS-1 on file 2021-05-28

= is there a registration (S-1/S-3 family) on file without a later withdrawal

no structured fee data on the live registrations, so this is a yes/no, not a size

Overhead supply

NOT COMPUTEDno warrant count tagged in XBRL

= warrant shares outstanding divided by current shares outstanding

absence of a tag is not proof of absence of warrants

Historical dilution

LOW+20% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

Cash need

MEDIUM~8.6 months of runway

= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 89.3M shares as of Oct 26, 2026 (10-Q).

⊙

EVIDENCE — filed/published fact

SourceSEC XBRL, cover-page share count

Fielddei:EntityCommonStockSharesOutstanding

As of2026-10-26

HowThe newest cover-page count as filed. It is used as the current count only while it is no more than about 15 months older than the company’s newest periodic filing; the float checker applies a 200-day rule and sets it beside the balance-sheet count.

Open the source document →

Cash runway

~9 months of cash left

burning $12.2M / quarter

Full breakdown: cash runway tool · source filing →

Warrants

Tranche	Warrants	Exercise price	Term	Notes
Public Warrant	9.2M	$11.5	—	—
Private Placement Warrants	5.0M	$11.5	—	—

Tranches exactly as the company dimensioned them in its 10-Q filed Nov 3, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Balance-sheet fair value of warrants: $0 as of Sep 30, 2026.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Nov 3, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding	89.3M	Oct 26, 2026
+ Public Warrant (if exercised)	9.2M	May 7, 2021
+ Private Placement Warrants (if exercised)	5.0M	May 7, 2021
Fully diluted estimate	103.5M	+15.9% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

Last 12 months: 0 executed · 0 registered.

EXECUTEDSep 16, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →

UPDATEJun 13, 2022Prospectus update — often a resale registration, not necessarily new capital424B3 →

EFFECTIVEJun 10, 2022SEC declared a registration effective — selling can beginEFFECT →

UPDATEMay 19, 2022Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEMay 10, 2022Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEMar 22, 2022Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEMar 17, 2022Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEJan 28, 2022Prospectus update — often a resale registration, not necessarily new capital424B3 →

EFFECTIVEJan 27, 2022SEC declared a registration effective — selling can beginEFFECT →

UPDATEDec 20, 2021Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEAug 16, 2021Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEJun 8, 2021Prospectus update — often a resale registration, not necessarily new capital424B3 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full SRTA workspace

Free to use. No account, no card.